Tuesday • May 17, 2016

7:00 pm EASTERN • 6:00 pm CENTRAL
5:00 pm MOUNTAIN • 4:00 pm PACIFIC

Click HERE to Join Tonight's Webinar!

If you are prompted for an EVENT NUMBER:  719 939 283

A certified one-hour live webinar for radiologists, radiologic technologists, neurologists, primary care physicians, and other healthcare providers who diagnose and manage patients with movement disorders.

Format:	Live Webinar
Credit:	1.0 AMA PRA Category 1
Credit:	1.0 ARRT Category A
Tuition:	none

Course Overview
Contrast-enhanced imaging is essential for the diagnosis and management of a multitude of diseases. Significant advancements in the detection and differentiation of disease have been made in the last decade using new and evolving contrast-enhanced imaging applications and techniques.

Current Concepts in Molecular Imaging of Parkinson’s Disease and Movement Disorders will include discussion of the movement disorder spectrum and implications for diagnosis and treatment; how the role of molecular imaging identifies biomarkers used to assess treatment response for patients with movement disorders; mechanism of dopamine transport in the setting of movement disorders; best practices for acquiring high-quality dopamine transporter imaging; and the role of automated image quantification in dopamine transporter imaging. Review of patient cases will supplement the lecture.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe the movement disorder spectrum and implications for diagnosis and treatment
• Discuss the benefits of molecular imaging for Parkinson’s disease and other movement disorders
• Explain the mechanism of dopamine transport and best practices for acquiring dopamine transporter images

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and International Center for Postgraduate Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Physicians
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Accreditation Council for CME (EACCME®)
The UEMS-EACCME® has mutual recognition agreements with the American Medical Association (AMA) for live events and e-learning materials. For more information go to http://www.uems.eu/uems-activities/accreditation/eaccme.

Radiologic Technologists
This program has been approved by the American Society of Radiologic Technologists (ASRT) for 1.0 hour of ARRT Category A continuing education credit.

How to Enroll and Participate
This program is offered by ICPME through WebEx webinar service at no charge to the learner.

Credit cannot be granted for group viewing. To receive credit, each attendee must sign in on a separate computer.

• Click ENROLL NOW and follow the registration instructions to register with ICPME.
• You will receive an email from ICPME confirming your registration.
• At the end of the registration process, click on ACCESS WEBINAR to complete the pre-course survey as well as to register on the ICPME WebEx site.
• Detailed log-in instructions will be sent to you via e-mail the day before the webinar.

Credit

• To receive credit, each participant must attend the entire session and complete the postcourse evaluation within 7 days after the presentation.
• Upon verification of your participation from the Webex event report, you will receive an email from ICPME two weeks after the event with instructions to print your certificate of credit. You will not be able to print your certificate until that time.
• Your certificate of credit will remain in your account at www.icpme.us as a permanent record of your participation.

Faculty
Kevin M. Biglan, MD, MPH

Dr. Biglan is Professor of Neurology and the Associate Chair for Clinical Research in the Department of Neurology and the Center for Human Experimental Therapeutics at the University of Rochester School of Medicine and Dentistry in Rochester, New York. He also serves as Director of the National Parkinson Foundation Center of Excellence and Director of the Huntington Disease Society of America Center of Excellence at the University of Rochester.

He has been actively involved in the development of telemedicine for the provision of care in patients with Parkinson’s disease and for identifying disease modifying therapy in Parkinson's disease and Huntington's disease. He has been at the forefront of establishing the feasibility of telemedicine in Parkinson’s disease and Huntington’s disease, the expansion of its use for clinical care, and the validation of clinical trial outcomes assessed via telemedicine.

Dr. Biglan is actively involved in the design, conduct and analysis of clinical trials in movement disorders, having been involved in more than 15 clinical trials. He was the co-Principal Investigator on the NINDS-sponsored first multicenter clinical trial in pre-symptomatic individuals carrying the mutation for Huntington’s disease (PREQUEL) and is the current PI for the Data Coordination Center for the NINDS-sponsored Phase III trial of isradipine in early Parkinson’s disease (STEADY-PD3).

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

The faculty has reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Kevin M. Biglan, MD, MPH, has received research grants from GE Healthcare not related to this activity.

The following planners and managers have reported NO financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:                                                            

Trace Hutchison, PharmD                                                   Victoria Phoenix, BS

Linda McLean, MS                                                               Jan Schultz, RN, MSN, CCMEP

Samantha Mattiucci, PharmD, CCMEP                              Judi Smelker-Mitchek, RN, BSN

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Questions
For questions regarding this program, please contact ICPME:
Email: information@icpmed.com
Phone: 607-257-5860 X10

Jointly provided by

               
 

This activity is supported by an independent educational grant from GE Healthcare

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.